Increasing Incidence of Endometrial and Breast Cancer: The rising number of cases of endometrial and breast cancers globally is a significant driver for the progesterone market. For instance, in the U ...
FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025.
Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).
Understanding biosimilars, biologics, and the challenges surrounding their regulation and pricing in the pharmaceutical ...
Ronan J. Kelly, MD, MBA, discusses the targeted therapy options that have become available for patients with gastric, ...
Dr. Chandler Park discusses the importance of genetic testing and personalized care in patients with genitourinary cancers.
San Antonio Breast Cancer Symposium 2024 provided multiple updates in the field of HER2-positive breast cancer, including novel treatments, new treatment regimens and more.See Healio’s highlights in H ...
Holdings announced its plans to advance the development of its proprietary Antibody Drug Conjugate (ADC) platform ...
3d
GlobalData on MSNFibroGen sells China unit to AstraZeneca for $160mAstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...
Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, provides new insights on the role of TROP2-directed antibody drug conjugates (ADCs) for patients with breast cancer.
Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results